Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://rowanaehza.bluxeblog.com/70005134/conolidin-to-replace-traditional-painkillers-options